Related Experiment Video
Updated: Apr 18, 2026
08:46
Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives
Published on: September 16, 2021
6.9K
Tocotrienol preserves ovarian function in cyclophosphamide therapy
H S Saleh1, E Omar2, G R A Froemming3
1Faculty of Health Science, Universiti Teknologi MARA, Puncak Alam, Selangor, Malaysia Department of Biology, Faculty of Pure Science Education, Thi-Qar University, Thi-Qar, Iraq.
Human & Experimental Toxicology
|January 15, 2015
Summary
Tocotrienol (T3) protects ovarian function during chemotherapy. Co-administration of T3 with cyclophosphamide (CPA) preserved ovarian size and reversed chemotherapy-induced damage, suggesting T3’s potential for fertility preservation.
Area of Science:
- Reproductive biology
- Pharmacology
- Oncology
Background:
- Cyclophosphamide (CPA) chemotherapy is known to cause ovarian failure and infertility.
- Tocotrienol (T3), an antioxidant and anti-inflammatory agent, has potential but unproven roles in ovarian protection during chemotherapy.
Purpose of the Study:
- To investigate the protective effects of Tocotrienol (T3) on female fertility during cyclophosphamide (CPA) treatment.
Main Methods:
- Sixty female mice were divided into five groups: saline, corn oil, T3 only, CPA, and CPA + T3.
- Treatments were administered for 30 days, followed by gonadotrophin-induced ovulation.
- Ovaries were collected and histologically examined.
Main Results:
- CPA significantly reduced ovarian size compared to controls (p ≤ 0.005).
- Concurrent T3 administration with CPA preserved ovarian size (p ≤ 0.005).
- CPA caused abnormal folliculogenesis, reduced ovulation, edema, and inflammation, which were reversed by T3.
Conclusions:
- Co-administration of T3 with CPA protects ovarian morphology and function in vivo.
- These findings elucidate CPA's ovarian effects and suggest T3's potential for fertility preservation during chemotherapy.
Related Concept Videos
01:30Hormonal Control of the Ovarian Cycle
7.8K
The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
7.8K
01:27Ovarian Cycle
5.8K
The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...
5.8K
02:07Oogenesis
71.8K
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
71.8K
01:22Hormonal Regulation of the Menstrual Cycle
2.5K
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
2.5K
02:34Inhibition of Cdk Activity
6.3K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.3K
01:28Infertility in Females
5.1K
Female infertility is defined as the inability to conceive after a year of regular, unprotected intercourse and affects about 10–15% of couples worldwide. The primary cause of female infertility is ovulatory disorders, which hinder the release of eggs. These disorders can be classified as hypothalamic amenorrhea, polycystic ovarian syndrome (PCOS), premature ovarian failure, and hyperprolactinemic anovulation disorders.
Endometriosis, a condition characterized by abnormal growth of...
Endometriosis, a condition characterized by abnormal growth of...
5.1K